|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2008-3-4
|
|
pubmed:abstractText |
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer related mortality worldwide. The incidence is dramatically increasing and no effective systemic treatments are available accentuating the urgent need for novel treatment approaches. A growing body of evidence suggest that COX-2 signaling is implicated in carcinogenesis and this study was conducted to evaluate the potential of selective COX-2 inhibition for the treatment and prevention of HCCs.
|
|
pubmed:language |
ger
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0070-4113
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
257-68
|
|
pubmed:meshHeading |
pubmed-meshheading:18314623-Animals,
pubmed-meshheading:18314623-Antineoplastic Agents,
pubmed-meshheading:18314623-Carcinoma, Hepatocellular,
pubmed-meshheading:18314623-Cyclooxygenase 2,
pubmed-meshheading:18314623-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:18314623-Disease Models, Animal,
pubmed-meshheading:18314623-Drug Design,
pubmed-meshheading:18314623-Humans,
pubmed-meshheading:18314623-Liver Neoplasms,
pubmed-meshheading:18314623-Rats,
pubmed-meshheading:18314623-Thiazines,
pubmed-meshheading:18314623-Thiazoles
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
[Significance of cyclooxygenase-2 as a chemotherapeutic target in hepatocellular carcinoma].
|
|
pubmed:affiliation |
Pathologisches Institut, Universitäitsklinikum Heidelberg.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
